Paroxetine is a new compound in the group of the selective serotonin-reuptake inhibitors. The results of several open and double-blind control-group studies demonstrate clear antidepressive efficacy of paroxetine. However, most data were collected in samples of outpatients. To overcome this restriction, a six-week double-blind control-group study, comparing 30 mg paroxetine with 150 mg amitriptyline per day, was performed in a sample of inpatients suffering from major depression. Generally speaking, the efficacy analysis of 160 patients was not able to demonstrate statistically significant differences in the antidepressive activity of paroxetine or amitriptyline, either with respect to the total score on the Hamilton Depression Scale (HAMD) and the Clinical Global Impressions or with respect to the subscores of the HAMD. One exception was the retardation subscore, in which amitriptyline showed a greater degree of reduction. Both drugs had a characteristic side-effect profile. Paroxetine was characterized by a lack of anticholinergic side-effects and a higher rate of nausea.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2007-1014346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Induced Myoclonus: A Systematic Review.
Medicina (Kaunas)
January 2025
Neurology Department, Cooper University Hospital, Camden, NJ 08103, USA.
: Myoclonus is already associated with a wide variety of drugs and systemic conditions. As new components are discovered, more drugs are suspected of causing this disabling abnormal involuntary movement. This systematic review aims to assess the medications associated with drug-induced myoclonus (DIM).
View Article and Find Full Text PDFAntidepressant use during pregnancy and birth outcomes: analysis of electronic health data from the UK, Norway, and Sweden.
medRxiv
October 2024
MRC Integrative Epidemiology Unit, Oakfield House, University of Bristol, BS8 2BN Florence Z Martin PhD student Department of Biomedicine, Aarhus University, Høegh-Guldbergs Gade 10, 8000 Aarhus, Denmark Viktor H Ahlqvist postdoctoral fellow MRC Integrative Epidemiology Unit, University of Bristol, BS8 2BN Paul Madley-Dowd research fellow Solnavägen 1 E, 11365 Stockholm Michael Lundberg statistician Marcus Thranes gate 6, 0473 Oslo Jacqueline M Cohen senior researcher Marcus Thranes gate 6, 0473 Oslo Kari Furu research professor Centre for Academic Mental Health, Canynge Hall, University of Bristol, BS8 2PN Dheeraj Rai professor of neurodevelopmental psychiatry Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT Harriet Forbes assistant professor School of Psychological Science, University of Bristol, BS8 1TU Kayleigh E Easey senior lecturer Myrens verksted 2, 0473 Oslo Siri E Håberg centre director School of Psychology, University of Exeter, EX4 4QG Gemma C Sharp associate professor of epidemiology Solnavägen 1 E, 11365 Stockholm Cecilia Magnusson adjunct professor Myrens verksted 2, 0473 Oslo Maria C Magnus researcher.
Article Synopsis
- The study investigates how using antidepressants during pregnancy impacts various birth outcomes, including stillbirth and preterm delivery.
- It analyzed data from over 2.5 million births across the UK and Scandinavia, discovering that 4.8% of deliveries involved mothers who used antidepressants.
- Results indicate a slight increase in risks for negative outcomes like stillbirth and low Apgar scores linked to maternal antidepressant use, but these risks remained low overall and might be influenced by underlying mental health conditions.
[Serotonin syndrome secondary to the association of paroxetine and amitriptyline: a case report].
Pan Afr Med J
November 2024
Faculté de Médecine et de Pharmacie Oujda, Université Mohammed Premier, Oujda, Maroc.
Article Synopsis
- Serotonin syndrome is a potentially dangerous condition caused by certain medications that increase serotonin levels, leading to a mix of confusing symptoms that can mimic other disorders.* -
- A specific patient case demonstrated symptoms like confusion, agitation, and muscle spasms after taking both paroxetine and amitriptyline simultaneously.* -
- The case emphasizes the need for healthcare professionals to be aware of serotonin syndrome's symptoms for prompt diagnosis and treatment to improve patient outcomes.*
Prevalence of strong anticholinergic use in residents with and without cognitive impairment and frailty: Analysis from 106 nursing homes in 12 Asia-Pacific and European countries.
Arch Gerontol Geriatr
January 2025
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Article Synopsis
- * Approximately 17.4% of residents used at least one strong anticholinergic medication, with significant variation across countries (from 1.3% in China to 27.1% in Italy).
- * The findings indicated higher usage among residents with cognitive impairment and those classified as most frail, suggesting the need for targeted deprescribing to minimize medication-related risks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!